Use of composition for enhancing anticancer effect, comprising ERRy inhibitor as active ingredient
The present invention relates to a pharmaceutical composition for inhibiting the resistance of liver cancer to sorafenib and enhancing an anticancer effect, comprising an Estrogen-related receptor γ (ERRγ) inhibitor as an active ingredient. The present invention can be effectively used as a pharmaceutical composition for treating sorafenib-resistant advanced liver cancer.
1 . A method for diagnosis and treatment of sorafenib-resistant liver cancer, comprising the following steps:
(a) measuring an expression level of mRNA of an estrogen-related receptor γ (ERRγ) gene or a protein expressed therefrom in a biological sample isolated from a test patient with liver cancer;
(b) comparing the measured expression level of the ERRγ mRNA and/or the measured level of ERRγ protein of the test patient of step (a) with a reference expression level of ERRγ mRNA and/or a reference level of ERRγ protein, said reference expression level of ERRY mRNA and/or a reference level of ERRγ protein being obtained from a reference patient with a liver cancer other than sorafenib-resistant liver cancer,
wherein a higher measured expression level of the ERRγ mRNA than the reference expression level and/or a higher measured level of ERRγ protein than the reference level indicates that the test patient has sorafenib-resistant liver cancer; and
(c) administering to the test patent who is determined to have sorafenib-resistant liver cancer, (i) an agent capable of inhibiting ERRγ protein activity or ERRγ gene expression; (ii) a combination of sorafenib and an agent capable of inhibiting ERRγ protein activity or ERRγ gene expression.
2 . The method of claim 1 , wherein the biological sample comprises liver tissue, liver cells, whole blood, plasma, or serum.
3 . A method selected from the group consisting of:
(a) preventing or inhibiting a development of sorafenib resistance in a liver cancer patient who is prescribed for sorafenib treatment or underwent sorafenib treatment; and
(b) enhancing sorafenib treatment of a liver cancer patient,
said method comprising administering to the liver cancer patient an effective amount of an inverse agonist against estrogen-related receptor γ (ERRγ),
wherein the inverse agonist against ERRγ is a compound of the following Formula 1 or a pharmaceutically acceptable salt thereof:
4 . The method of claim 3 , which further comprises administering sorafenib, wherein the inverse agonist is administered simultaneously with sorafenib, separately, or sequentially.
5 . A method of treating liver cancer in a subject in need thereof, comprising:
administering an effective amount of an inverse agonist against estrogen-related receptor γ (ERRγ),
wherein the inverse agonist against ERRγ is a compound of the following Formula 1 or a pharmaceutically acceptable salt thereof:
6 . The method of claim 1 , wherein the agent is administered simultaneously with sorafenib, separately, or sequentially.
7 . The method of claim 5 , wherein the inverse agonist is administered simultaneously with sorafenib, separately, or sequentially.